{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T06:28:17Z","timestamp":1762064897187,"version":"build-2065373602"},"reference-count":18,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T00:00:00Z","timestamp":1662249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Migraine is one of the most frequent neurological and vascular disorders, with an estimated global prevalence of 14 [...]<\/jats:p>","DOI":"10.3390\/jcm11175225","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T20:52:51Z","timestamp":1662497571000},"page":"5225","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Management of Migraine"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5113-2017","authenticated-orcid":false,"given":"Maria","family":"Albanese","sequence":"first","affiliation":[{"name":"Regional Referral Headache Center, Neurology Unit, University Hospital Tor Vergata, 00133 Rome, Italy"},{"name":"Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1111\/j.1526-4610.2005.4501001.x","article-title":"Migraine: Epidemiology, impact, and risk factor for progression","volume":"45","author":"Lipton","year":"2005","journal-title":"Headache"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s10194-020-01130-5","article-title":"European headache federation consensus on the definition of resistant and refractory migraine: Developed with the endorsement of the European Migraine & Headache Alliance (EMHA)","volume":"21","author":"Sacco","year":"2020","journal-title":"J. Headache Pain"},{"key":"ref_3","unstructured":"GBD 2019 Diseases and Injuries Collaborators (2020). Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: A systematic analysis for the global burden of disease study 2019. Lancet, 396, 1204\u20131222."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","article-title":"Migraine remains second among the world causes of disability, and first among young women: Findings from GBD2019","volume":"21","author":"Steiner","year":"2020","journal-title":"J. Headache Pain"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1474-4422(17)30435-0","article-title":"The pathophysiology of migraine: Implications for clinical management","volume":"17","author":"Charles","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_6","first-page":"419","article-title":"Unmet needs in the acute treatment of migraine attacks and the emerging role of calcitonin gene-related peptide receptor antagonists: An integrative review","volume":"33","author":"Moriarty","year":"2020","journal-title":"J. Am. Assoc. Nurse Pract."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Albanese, M., and Mercuri, N.B. (2022). Could the New Anti-CGRP Monoclonal Antibodies Be Effective in Migraine Aura? Case Reports and Literature Review. J. Clin. Med., 11.","DOI":"10.3390\/jcm11051228"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s10194-022-01396-x","article-title":"Fremanezumab in the prevention of high-frequency episodic and chronic migraine: A 12-week, multicenter, real-life, cohort study (the FRIEND study)","volume":"23","author":"Barbanti","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_9","first-page":"1","article-title":"Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: The 12-month observational, longitudinal, cohort multicenter GARLIT experience","volume":"28","author":"Altamura","year":"2022","journal-title":"J. Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","article-title":"European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention\u20142022 update","volume":"23","author":"Sacco","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1007\/s10072-022-06260-z","article-title":"Ditans: A new prospective for the therapy of migraine attack?","volume":"43","author":"Viticchi","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1007\/s10072-022-06184-8","article-title":"Gepants\u2014A long way to cure: A narrative review","volume":"43","author":"Altamura","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1007\/s00415-021-10772-7","article-title":"GARLIT Study Group collaborators. When should we consider chronic patients as non-responders to monoclonal antibodies targeting the CGRP pathway?","volume":"269","author":"Altamura","year":"2022","journal-title":"J. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1177\/0333102416639515","article-title":"Invasive pericranial nerve interventions","volume":"36","author":"Ambrosini","year":"2016","journal-title":"Cephalalgia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"100361","DOI":"10.1016\/j.bbih.2021.100361","article-title":"Roles of calcitonin gene-related peptide in the skin, and other physiological and pathophysiological functions","volume":"18","author":"Kim","year":"2021","journal-title":"Brain Behav. Immun. Health"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s10194-019-0979-y","article-title":"CGRP and migraine from a cardiovascular point of view: What do we expect from blocking CGRP?","volume":"20","author":"Favoni","year":"2019","journal-title":"J. Headache Pain"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s10194-021-01330-7","article-title":"Inflammatory complications of CGRP monoclonal antibodies: A case series","volume":"22","author":"Ray","year":"2021","journal-title":"J. Headache Pain"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1177\/0333102415620908","article-title":"Pathophysiological targets for non-pharmacological treatment of migraine","volume":"36","author":"Coppola","year":"2016","journal-title":"Cephalalgia"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/17\/5225\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:23:10Z","timestamp":1760142190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/17\/5225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,4]]},"references-count":18,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["jcm11175225"],"URL":"https:\/\/doi.org\/10.3390\/jcm11175225","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2022,9,4]]}}}